Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute - sprookjes - yvandenbroek - TriplyDB

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

http://www.wikidata.org/entity/Q28275506

about

sameAs

Health-related quality of life in Hodgkin lymphoma: a systematic review Hodgkin lymphoma, version 2.2015.A note from history: Landmarks in history of cancer, part 7.Bystander cells and prognosis in Hodgkin lymphoma. Review based on a doctoral thesis.Methyl-GAG, ifosfamide, methotrexate and etoposide (MIME) as salvage therapy for Hodgkin's disease and non-Hodgkin's lymphoma. The Swedish Lymphoma Study Group.Single agent palliative chemotherapy for end-stage Hodgkin's disease.Treatment of MOPP-refractory Hodgkin's disease with vinblastine, doxorubicin, bleomycin, CCNU, and dacarbazine.Hodgkin lymphoma: an update on its biology with new insights into classification.A Historical Tale of Two Lymphomas: Part I: Hodgkin lymphoma Second malignancies following testicular cancer, ovarian cancer and Hodgkin's disease: an international collaborative study among cancer registries.New treatments for Hodgkin's disease.Second primary breast cancer after Hodgkin's disease.The long-term effects of MVPP chemotherapy for Hodgkin's disease on bone marrow function.ChlVPP combination chemotherapy for Hodgkin's disease: long-term results.A randomised study of adjuvant chemotherapy after mantle radiotherapy in supradiaphragmatic Hodgkin's disease PS IA-IIB: a report from the Manchester lymphoma group Hodgkin's disease mortality in Europe Five years' experience with ChlVPP: effective low-toxicity combination chemotherapy for Hodgkin's disease.Tumor-Targeted Synergistic Blockade of MAPK and PI3K from a Layer-by-Layer Nanoparticle.The role of radiation therapy in Hodgkin disease: experience and controversy. The 54th annual Janeway Lecture: 1989.Prognostic factors for survival in stage IIIB and IV Hodgkin's disease: a multivariate analysis comparing two specialist treatment centres.Changing patterns of relapse in Hodgkin's disease.Glucocorticoid-induced apoptosis of healthy and malignant lymphocytes.The role of autografting in lymphoma Glomerulonephritis preceding late relapse of Hodgkin's disease.Gingival enlargement as an early diagnostic indicator in therapy-related acute myeloid leukemia: A rare case report and review of literature Classical Hodgkin's lymphoma in adults: guidelines of the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation on initial work-up, management, and follow-up A risk-adapted, response-based approach using ABVE-PC for children and adolescents with intermediate- and high-risk Hodgkin lymphoma: the results of P9425.Is BEACOPP better than ABVD?Classical Hodgkin's lymphoma arising in different host's conditions: pathobiology parameters, therapeutic options, and outcome.Autologous marrow transplantation for Hodgkin's disease current techniques and prospects.State of the art in the treatment of Hodgkin lymphoma.Chemotherapy dosing in overweight and obese patients with cancer.Classical Hodgkin's lymphoma: past, present and future perspectives.Recent advances in Hodgkin lymphoma: interim PET and molecular-targeted therapy.Bleomycin pulmonary toxicity in adult Saudi patients with Hodgkin's lymphoma.Outcome of pediatric advanced Hodgkin lymphoma treated with ABVD and predictors of inferior survival: a multicenter study of 186 patients.Malignant lymphomas in children and adolescents.Selection of patients with Hodgkin's disease and non-Hodgkin's lymphoma for bone marrow transplantation.Osteonecrosis in patients with malignant lymphoma. A review of 31 cases.A retrospective analysis of combination chemotherapy consisting cyclophosphamide, vincristine, prednisolone and procarbazine (C-MOPP) for pretreated aggressive non-Hodgkin lymphoma.

P2860

Q26740480-387239BF-0CEC-4603-BDDF-2038AAA93E4C Q26740480-B0E0BCEF-FFBB-4683-AA44-9E1FED83E157 Q30769157-7A4AA339-5124-439B-A365-745321BF39A0 Q30769157-B75D8C06-E827-4114-97CE-70DDE3564E36 Q30931923-85BA6290-00C2-4807-85C0-D38FAF8E8047 Q33208378-4D5E7F02-0AE6-40F7-ABEC-5B3774D11A36 Q33407458-8C1603CF-CE88-4B5C-B0A1-FEA1E4BA4B10 Q33476020-5D5908E0-6DCC-4E09-A316-C0C05EEB79F6 Q33476090-D6ECCC7C-8CF1-408D-851B-E38714673D2D Q33588862-33F6D2AA-82A9-427F-9BD7-D49DA5D24C00 Q33588862-D723F6A4-1B5A-45C4-8179-5D91A322F165 Q34479660-02DF452A-D1E9-450A-B285-E92848D6B7DF Q34479660-255504F8-3C5D-4623-81C6-F12D33419C30 Q34690717-9A298289-28A4-4463-AF66-E1498FE17967 Q34696326-476595B6-F0A2-4F20-B501-86E33D017BC9 Q35634560-76B5F91B-27A2-4A24-8FB4-27F7B7B2F9BA Q35634560-E886D789-2741-424F-AF5E-02B7A700C7F5 Q35982854-402EE434-A92D-4A6C-9B2D-27D8C539B405 Q35982854-ECBCD962-A9A0-440C-8269-2EC232FB512F Q35983167-BAADACE7-0B0B-4805-880E-B0F1AD9C00F5 Q35983167-C9D3BBF7-57D1-4791-83DF-13C6B2C1B7F9 Q35991659-021E4C60-4685-4FC9-9B45-52CDD16378AC Q35991659-2B223DD1-5883-4DFF-B1AE-10ED356B3FF3 Q35993914-1D759BDC-9504-479E-AF44-CBAFE3B22D62 Q35993914-DA823F04-83E7-4636-BD15-6C69B5612B3A Q36046574-5DBCE281-D650-48B6-B638-CE257AACB3FE Q36046574-9129D6C0-3F1F-49D0-9D23-BD35A2AC7DF7 Q36219160-48ED0033-109A-4A69-A454-0326C099C7F0 Q36219160-F1E6DEC9-F91B-4158-A1A0-F7354F1BD260 Q36290519-23F47D56-C0D6-46C6-89CC-45900956FB69 Q36466659-9637A742-85EE-481A-B7AB-D2C884556D85 Q36466659-974BC623-7E3D-4B23-BF54-17242B7E2A07 Q36467170-BEC6F468-3F7A-470C-9C59-9DBCD7E6D9BB Q36467170-FAE3C64A-5305-457A-AC21-BCCEF5BE4541 Q36628641-2DBABF27-4842-4A56-B169-51E7EDC3228F Q36628641-B7B509B0-CF2D-4E0D-B986-DB44143E1273 Q36679013-199DEFB8-C0E6-4969-AA9E-8F235694CA7D Q36679013-3BD5F8C0-370C-4439-92E4-71F8E5249B6A Q36722045-CCBD13D4-ADC6-42D5-A770-7D2824B1221C Q36722045-F014B822-5193-4978-8030-BD3604C97AC8

P2860

Curability of advanced Hodgkin's disease with chemotherapy. Long-term follow-up of MOPP-treated patients at the National Cancer Institute

http://www.wikidata.org/entity/Q28275506

description

1980 nî lūn-bûn

@nan

1980 թուականի Մայիսին հրատարակուած գիտական յօդուած

@hyw

1980 թվականի մայիսին հրատարակված գիտական հոդված

@hy

1980年の論文

@ja

1980年論文

@yue

1980年論文

@zh-hant

1980年論文

@zh-hk

1980年論文

@zh-mo

1980年論文

@zh-tw

1980年论文

@wuu

name

Curability of advanced Hodgkin ...... the National Cancer Institute

@ast

Curability of advanced Hodgkin ...... the National Cancer Institute

@en

Curability of advanced Hodgkin ...... the National Cancer Institute

@nl

type

label

Curability of advanced Hodgkin ...... the National Cancer Institute

@ast

Curability of advanced Hodgkin ...... the National Cancer Institute

@en

Curability of advanced Hodgkin ...... the National Cancer Institute

@nl

altLabel

Curability of Advanced Hodgkin's Disease with Chemotherapy

@ast

Curability of Advanced Hodgkin's Disease with Chemotherapy

@en

prefLabel

Curability of advanced Hodgkin ...... the National Cancer Institute

@ast

Curability of advanced Hodgkin ...... the National Cancer Institute

@en

Curability of advanced Hodgkin ...... the National Cancer Institute

@nl

P1433

Q28275506-41E76FD2-CB85-48AA-8A34-2C527DB0A592

P1476

Q28275506-12A13DDF-D6A1-469A-A53D-3A98BC190957

Q28275506-D14F0E03-558F-46F5-9741-B2E147CE102F

P2093

Q28275506-022BA510-A616-4113-8728-E718199A8EE4

Q28275506-042273D7-BA17-4CA8-A250-6094957535FA

Q28275506-04BFF98F-EB47-4F68-9187-5179800FFBCE

Q28275506-302F50BA-198C-471F-9213-D77EBBF6E16A

Q28275506-4C8A9357-0EB3-4E72-B52A-C9164DFE7DB0

Q28275506-74F3F995-4832-4BA2-9506-C4CC95B8C88C

Q28275506-85D24354-9D15-4500-9402-0607DFD5319C

Q28275506-AB9C3A19-EF85-4D7C-9100-0E22379824B1

Q28275506-BA1CDE4B-4728-48E8-9331-537E2F82D34E

Q28275506-F49AE59A-4C4F-4CA4-8C98-35C8D3683F4F

P304

Q28275506-3E6139EE-720B-4A76-9E94-CEB94592B478

Q28275506-F0394B70-5D8C-4433-BD97-6462B686B2E6

P31

Q28275506-58C633BF-9C12-4992-904F-62709E6E4400

P3181

Q28275506-B0B43173-B03B-4852-B2BA-F6C0F277F38C

P356

Q28275506-34937219-200F-4651-BCAC-BCEC71AC3254

P407

Q28275506-A8F57D12-03D3-4C3E-BFC2-1855D17B6A5A

P433

Q28275506-67D25D62-31E9-4B2A-9B6D-B60E899C6EEB

P478

Q28275506-72A459B2-66BE-44E0-937F-C55840970935

P577

Q28275506-6B96AE74-5F6F-4E7A-9894-F03D7A448123

Q28275506-B7D63D3C-4867-4648-A53D-EB3F2848185A

P698

Q28275506-BF037F82-E93F-48C2-BFAB-BB42709BA4A0

P921

Q28275506-5468A7A7-DD19-4E23-AE2F-C952CB6A18E9

P3181

P356

0003-4819-92-5-587

P1433

Annals of Internal Medicine

P1476

Curability of Advanced Hodgkin's Disease with Chemotherapy

@en

Curability of advanced Hodgkin ...... the National Cancer Institute

@en

P2093

C W Berard

http://www.w3.org/2001/XMLSchema#string

E Frei

http://www.w3.org/2001/XMLSchema#string

G P Canellos

http://www.w3.org/2001/XMLSchema#string

J H Moxley

http://www.w3.org/2001/XMLSchema#string

P P Carbone

http://www.w3.org/2001/XMLSchema#string

R C Young

http://www.w3.org/2001/XMLSchema#string

R M Simon

http://www.w3.org/2001/XMLSchema#string

S M Hubbard

http://www.w3.org/2001/XMLSchema#string

V T DeVita

http://www.w3.org/2001/XMLSchema#string

VINCENT T. DEVITA

http://www.w3.org/2001/XMLSchema#string

P304

587

http://www.w3.org/2001/XMLSchema#string

587-95

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

4235962

http://www.w3.org/2001/XMLSchema#string

P356

10.7326/0003-4819-92-5-587

http://www.w3.org/2001/XMLSchema#string

P407

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

92

http://www.w3.org/2001/XMLSchema#string

P577

1980-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

6892984

http://www.w3.org/2001/XMLSchema#string

P921